GPR150 is an orphan Class A G protein-coupled receptor (GPCR) belonging to the Rhodopsin family. Based on phylogenetic analysis, GPR150 is predicted to bind gonadotropin-releasing hormone (GnRH I and GnRHII) 1, and shows evolutionary relationship to oxytocin/vasopressin receptors 2. The receptor is primarily expressed in the central nervous system 2. Clinically, GPR150 has emerged as a disease-relevant biomarker in multiple cancer types. In ovarian cancer, GPR150 promoter methylation occurs in approximately 27% of primary tumors (4/15 cases) and correlates with gene silencing, suggesting it functions as a potential tumor suppressor 3. In gastric cancer, GPR150 is part of a nine-gene orphan GPCR signature model that predicts prognosis and correlates with M2 macrophage infiltration and immune microenvironment composition 4. Similarly, in head and neck squamous cell carcinoma, aberrant GPR150 methylation independently correlates with overall survival and serves as a prognostic biomarker 5. Additionally, GPR150 expression is significantly downregulated in testicular tissue from infertile patients with nonobstructive azoospermia 6. These findings collectively indicate GPR150 functions as a tumor suppressor and fertility-associated gene with potential therapeutic significance.